Jordi Navarro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5835157/publications.pdf

Version: 2024-02-01

70	2,062	304743	254184
papers	citations	22 h-index	43 g-index

78	78	78	3590
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Gut Microbiota Linked to Sexual Preference and HIV Infection. EBioMedicine, 2016, 5, 135-146.	6.1	328
2	Dual treatment with lopinavirâ€“ritonavir plus lamivudine versus triple treatment with lopinavirâ€“ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infectious Diseases, The, 2015, 15, 785-792.	9.1	131
3	Dual treatment with atazanavirâ€“ritonavir plus lamivudine versus triple treatment with atazanavirâ€“ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infectious Diseases, The, 2015, 15, 775-784.	9.1	122
4	Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations. PLoS Pathogens, 2019, 15, e1007991.	4.7	119
5	Peripheral and lung resident memory T cell responses against SARS-CoV-2. Nature Communications, 2021, 12, 3010.	12.8	111
6	A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4 ⁺ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients. MBio, 2017, 8, .	4.1	105
7	The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 2015, 61, 403-408.	5.8	100
8	Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. Clinical Infectious Diseases, 2017, 65, 2112-2118.	5.8	88
9	Simplification to dual therapy (atazanavir/ritonavirâ€Š+â€Šlamivudine) versus standard triple therapy [atazanavir/ritonavirâ€Š+â€Štwo nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). Journal of Antimicrobial Chemotherapy, 2017, 72, 246-253.	3.0	57
10	Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection. Mucosal Immunology, 2019, 12, 232-246.	6.0	56
11	Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue. PLoS ONE, 2017, 12, e0175899.	2.5	50
12	Tropical Diseases Screening in Immigrant Patients with Human Immunodeficiency Virus Infection in Spain. American Journal of Tropical Medicine and Hygiene, 2013, 88, 1196-1202.	1.4	45
13	Risk of progression to high-grade anal intraepithelial neoplasia in HIV-infected MSM. Aids, 2015, 29, 695-702.	2.2	40
14	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Research, 2020, 174, 104694.	4.1	39
15	Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab. Nature Communications, 2019, 10, 3705.	12.8	38
16	Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4⁺T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2016, 213, 1008-1012.	4.0	36
17	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. Open Forum Infectious Diseases, 2016, 3, ofw059.	0.9	34
18	The effectiveness of electrocautery ablation for the treatment of highâ€grade anal intraepithelial neoplasia in <scp>HIV</scp>â€infected men who have sex with men. HIV Medicine, 2016, 17, 524-531.	2.2	33

#	Article	IF	Citations
19	Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort. HIV Medicine, 2019, 20, 237-247.	2.2	32
20	Epidemiology and Long-Term Survival in HIV-Infected Patients With Pneumocystis jirovecii Pneumonia in the HAART Era. Medicine (United States), 2015, 94, e681.	1.0	27
21	The role of oncogenic human papillomavirus determination for diagnosis of high-grade anal intraepithelial neoplasia in HIV-infected MSM. Aids, 2017, 31, 2227-2233.	2.2	27
22	Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2012, 67, 2479-2486.	3.0	24
23	Switching From a Protease Inhibitorâ€“based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapyâ€“suppressed Human Immunodeficiency Virusâ€“infected Individuals. Clinical Infectious Diseases, 2019, 69, 1320-1328.	5.8	23
24	Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. Journal of Antimicrobial Chemotherapy, 2015, 70, 1139-1145.	3.0	21
25	Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant. Open Forum Infectious Diseases, 2018, 5, ofx258.	0.9	21
26	Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice. AIDS Research and Human Retroviruses, 2019, 35, 513-518.	1.1	20
27	Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group. Journal of Antimicrobial Chemotherapy, 2014, 69, 1390-1396.	3.0	19
28	Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis <scp>C</scp> virus/<scp>HIV</scp>â€coinfected patients. HIV Medicine, 2015, 16, 211-218.	2.2	18
29	Neurological opportunistic infections and neurological immune reconstitution syndrome: impact of one decade of highly active antiretroviral treatment in a tertiary hospital. HIV Medicine, 2013, 14, 21-30.	2.2	17
30	Invasive Pneumococcal Disease in HIV-Infected Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 31-38.	2.1	17
31	Risk factors of high-grade anal intraepithelial neoplasia recurrence in HIV-infected MSM. Aids, 2017, 31, 1245-1252.	2.2	15
32	Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus. Pharmacotherapy, 2019, 39, 501-507.	2.6	15
33	Impact of Low-Level Viraemia on Virological Failure in HIV-1-Infected Patients with Stable Antiretroviral Treatment. Antiviral Therapy, 2016, 21, 345-352.	1.0	14
34	Epidemiological trends of HIV/HCV coinfection in Spain, 2015â€“2019. HIV Medicine, 2022, 23, 705-716.	2.2	14
35	Assessing main death pathways in T lymphocytes from HIV infected individuals. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83A, 648-658.	1.5	13
36	Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. Journal of Antimicrobial Chemotherapy, 2017, 72, 2850-2856.	3.0	13

#	Article	IF	Citations
37	Immune reconstitution inflammatory syndrome in HIV-infected patients with Pneumocystis jirovecii pneumonia. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 621-626.	0.5	13
38	Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study. Journal of Antimicrobial Chemotherapy, 2022, 77, 2265-2273.	3.0	13
39	Memory B cell dysregulation in HIV-1-infected individuals. Aids, 2018, 32, 149-160.	2.2	11
40	Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS. HIV/AIDS - Research and Palliative Care, 2016, Volume 8, 175-182.	0.8	10
41	Acute Leg Ischaemia in an HIV-Infected Patient Receiving Antiretroviral Treatment. Antiviral Therapy, 2017, 22, 89-90.	1.0	10
42	Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response. ELife, 0, 11, .	6.0	10
43	Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial. Journal of Clinical Medicine, 2020, 9, 1246.	2.4	9
44	Effectiveness of Efavirenz Compared with Ritonavir-Boosted Protease-Inhibitor-Based Regimens as Initial Therapy for Patients with Plasma HIV-1 RNA above 100,000 Copies/Ml. Antiviral Therapy, 2014, 19, 569-577.	1.0	8
45	Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns. PLoS ONE, 2017, 12, e0187893.	2.5	8
46	Brief Report: Effectiveness of Trichloroacetic Acid vs. Electrocautery Ablation for the Treatment of Anal High-Grade Squamous Intraepithelial Lesion in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 612-616.	2.1	8
47	Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. Journal of Infectious Diseases, 2020, 222, S8-S19.	4.0	8
48	Impact of an Adherence Program to Antiretroviral Treatment on Virologic Response in a Cohort of Multitreated and Poorly Adherent HIV-Infected Patients in Spain. AIDS Patient Care and STDs, 2014, 28, 537-542.	2.5	7
49	Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC. Journal of the International AIDS Society, 2014, 17, 19550.	3.0	6
50	Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 2444-2451.	3.0	6
51	Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping. Journal of Antimicrobial Chemotherapy, 2020, 75, 3517-3524.	3.0	6
52	HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. Journal of Biomedical Science, 2021, 28, 23.	7.0	6
53	Effects of Eradication of HCV on Cardiovascular Risk and Preclinical Atherosclerosis in HIV/HCV-Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 292-300.	2.1	5
54	Darunavir and Ritonavir Total and Unbound Plasmatic Concentrations in HIV-HCV-Coinfected Patients with Hepatic Cirrhosis Compared to Those in HIV-Monoinfected Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 6782-6790.	3.2	4

#	Article	IF	Citations
55	Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. Journal of Antimicrobial Chemotherapy, 2020, 75, 1955-1960.	3.0	4
56	Exploration of clients living with HIV needs for reporting on experiences with sex. Australian Journal of Cancer Nursing, 2020, 22, 570-576.	1.6	4
57	Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 493-498.	0.5	3
58	Incidencia de neoplasias en una cohorte espaÃ±ola de pacientes con infecciÃ³n por el virus de la inmunodeficiencia humana. Medicina ClÃnica, 2020, 155, 288-294.	0.6	3
59	Low frequency of cytomegalovirus (CMV) disease despite high prevalence of CMV viraemia in patients with advanced HIV infection: a clinical and immunological 48â€week followâ€up study. HIV Medicine, 2021, 22, 682-689.	2.2	3
60	Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy. HIV Clinical Trials, 2016, 17, 89-95.	2.0	2
61	Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIVâ€“HCV co-infected patients: final results of the Spanish BOC HIVâ€“HCV Study. International Journal of Infectious Diseases, 2016, 53, 46-51.	3.3	2
62	Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients. Clinical Infectious Diseases, 2020, 73, e2026-e2033.	5.8	2
63	Screening for asymptomatic STIs in HIV-infected men who have sex with men. Sexually Transmitted Infections, 2021, 97, 170-171.	1.9	2
64	Genotypic tropism testing of proviral <scp>DNA</scp> to guide maraviroc initiation in aviraemic subjects: 48â€week analysis of results from the <scp>PROTEST</scp> study. HIV Medicine, 2017, 18, 482-489.	2.2	1
65	FarmacologÃa de SymtuzaÂ® (DRV/c/FTC/TAF). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 10-16.	0.5	1
66	Exploratory study of an oral screening dysplasia program for HIV-infected men who have sex with men. Aids, 0, Publish Ahead of Print, .	2.2	1
67	Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 491-496.	0.3	0
68	APPLICATION OF CELL-OF-ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV-RELATED DIFFUSE LARGE B-CELL LYMPHOMAS. Hematological Oncology, 2017, 35, 156-157.	1.7	0
69	Epstein-Barr virus load in plasma is an early biomarker of HIV-related lymphomas. Hematological Oncology, 2017, 35, 330-330.	1.7	0
70	Long-Term Effectiveness of First-Line Antiretroviral Theraphy in a Cohort of HIV-1 Infected Patients. Journal of Antivirals & Antiretrovirals, 2012, 04, .	0.1	0